紫杉醇联合不同铂类治疗晚期食管癌疗效和毒副反应的比较  

Efficacy and adverse reactions of nedaplatin or cisplatin combined with paclitaxel in treatment of advanced esophageal cancer

作　　者：韩光锋[1] 段爱雄[1] 

机构地区：[1]安徽医科大学附属安庆医院,安徽安庆246003

出　　处：《现代肿瘤医学》2015年第22期3262-3265,共4页Journal of Modern Oncology

摘　　要：目的：观察紫杉醇分别联合顺铂、奈达铂治疗晚期食管癌的疗效和毒副反应。方法：收集58例Ⅳ期食管癌患者,分为紫杉醇联合顺铂组（TP）31例和紫杉醇联合奈达铂组（TN）27例,其中紫杉醇注射液135mg/m2,静脉滴注3小时,d1;顺铂25mg/m2,静脉滴注,d1~d3,奈达铂80mg/m2,d1;21天为1个周期。结果：紫杉醇＋顺铂组与紫杉醇＋奈达铂组有效率分别为37.10%和51.85%（P=0.315）;两组疾病控制率分别为77.42%和81.48%（P=0.703）;两组患者中位无进展生存期分别为6.8和7.8个月（P=0.678）;中位总生存期分别为10.4和11.4个月（P=0.412）,差异均无统计学意义。两组中恶心呕吐、食欲下降两种毒副反应发生率比较,差异有统计学意义（P值分别为0.009和0.007）。结论：紫杉醇联合顺铂或奈达铂治疗晚期食管癌有效率与生存期无统计学差异,但联合奈达铂方案胃肠道毒副反应较轻。Objective： To evaluate the efficacy and toxicity of the combination of paclitaxel and cisplatin or nedaplatin for patients with metastatic esophageal cancer. Methods： All 58 patients with metastatic esophageal cancer were divided into two groups. The patients received 135 mg / m2 paclitaxel over a 3h infusion on day 1,followed by 25 mg / m2 cisplatin On day 1 ~ 3,or 80 mg / m2 nedaplatin on day 1. The treatments were done every 3 weeks. Results： The response rates were 37. 10% and 51. 85%（ P = 0. 315）,and the disease control rates were 77. 42% and 81. 48%（ P =0. 703） in TP and TN groups respectively. The median progression free survival were 6. 8 months and 7. 8 months（ P= 0. 678）,and the median overall survival were 10. 4 months and 11. 4 months（ P = 0. 412） respectively. The differences all showed no significance. The rates of nausea and vomiting and loss of appetite were different in two groups（ P= 0. 009,P = 0. 007）. The differences were statistically significant. Conclusion： Paclitaxel combined with cisplatin or nedaplatin in the treatment of advanced esophageal cancer have the similar response rate and survival,however,nedaplatin regimen shows superiority in gastrointestinal side effects.

关 键 词：食管癌 紫杉醇 顺铂 奈达铂 

分 类 号：R735.1[医药卫生—肿瘤]